AEye Reports Third Quarter 2021 Financial Results
Announces Positive Product and Customer Momentum
“AEye is experiencing positive customer and partnership momentum,” commented
The webcast and accompanying slides will be accessible via the company’s website at https://investors.aeye.ai/.
Strategic Milestones for 2021
-
Financial
-
AEye completed its public debut by listing on Nasdaq (LIDR), raising more than$200 million , net of fees, to fund product development, increase scale, and support AEye’s growing customer base.
-
-
Product
-
AEye established new LiDAR industry performance standards for range, rate, and resolution in performance specification tests monitored, validated, and published byVSI Labs , one of the nation’s leading independent evaluators and advisors on active safety and automated vehicle technologies. -
AEye validated superior weather performance as documented in the journal, Atmosphere.
-
-
Manufacturing
-
ADAS:
AEye transitioned initial production of automotive B-samples ofAEye -based long-range LiDAR sensors to a Continental manufacturing line. The Continental HRL131 is on-track for large-scale series production in 2024. The HRL 131 will be manufactured, sold, and supported, under Continental’s name to its installed base of 25 ADAS customers/OEMs. -
Industrial:
AEye is on schedule to transition manufacturing of AEye’s 4Sight™ M sensor for industrial and mobility applications from AEye’sAdvanced Development Center inDublin, CA to Sanmina, AEye’s lead contract manufacturing partner, in the fourth quarter of 2021.
-
ADAS:
-
Customers and Partners - Continental announced the integration of AEye’s LiDAR technology into their full-stack (cameras, radar, lidar, and ECU) automotive-grade system for Level 2+ automated and autonomous driving applications – allowing Continental to sell a standalone high-performance long-range LiDAR sensor or as part of a complete ADAS system.
-
AEye announced a partnership with TuSimple to deploy AEye’s long-range, high-performance LiDAR for autonomous trucking applications. -
AEye announced integration of its adaptive LiDAR with the Nvidia DRIVE Platform for autonomous vehicles. -
AEye launched its adaptive LiDAR solutions for Intelligent Transportation Systems at theITS World Congress inHamburg in October:- Partnered with Seoul Robotics, a global leader in perception software, to integrate AEye’s adaptive LiDAR with Seoul Robotics’ SENSR perception software to deliver a complete solution for long-range object detection, classification, and perception.
- Collaborated with Intetra, a leading provider of end-to-end ITS solutions, to demonstrate how AEye’s software-definable LiDAR enables improved detection accuracy for automated tolling in all lighting, weather, and traffic conditions.
-
AEye is also working with ITS industry leaders such as Mitsubishi and Econolite.
-
AEye , as previously announced, is working with leaders in other industrial markets such as Komatsu (Construction) andHitachi (Rail) .
-
Governance
-
A new board of directors was elected, bringing to
AEye extensive public governance, legal, and financial management experience as well as deep domain expertise in the automotive, trucking, aerospace, and defense markets.
-
A new board of directors was elected, bringing to
- Scaling the Company
-
Innovation
-
AEye filed its 100th patent for groundbreaking concepts that meaningfully strengthen AEye’s IP protection and competitive position.
-
Q3 2021 Financials
The company closed the quarter with
Adjusted EBITDA is a non-GAAP financial measure. Refer to “Non-GAAP Financial Measures” for a discussion of Adjusted EBITDA and the financial tables below for reconciliations of Adjusted EBITDA to GAAP net loss, the most directly comparable GAAP financial measure.
Conference Call and Webcast Details
The webcast and accompanying slides will be accessible via the company’s website at https://investors.aeye.ai/.
The call is also accessible via telephone through the following details:
Dial in Information:
-
US/
CANADA Participant Toll-Free Dial-In Number: (844) 253-4108 -
US/
CANADA Participant International Dial-In Number: (225) 239-4721
Conference ID: 9789399
About
Non-GAAP Financial Measures
The non-GAAP measures provided in this press release should not be considered a substitute for, or superior to, measures of financial performance prepared in accordance with generally accepted accounting principles (GAAP) in
This presentation includes non-GAAP financial measures, including Adjusted EBITDA. Adjusted EBITDA is defined as GAAP net loss plus stock-based compensation, plus expenses related to the registration statement on Form S-1 on behalf of selling stockholders, plus change in fair value of embedded derivative and warrant liabilities, plus the gain on our PPP loan forgiveness, plus amortization and depreciation expense, plus interest expense, less interest income.
Forward-Looking Statements
Certain statements included in this press release that are not historical facts are forward-looking statements within the meaning of the federal securities laws, including the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements are sometimes accompanied by words such as “believe,” “continue,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “predict,” “plan,” “may,” “should,” “will,” “would,” “potential,” “seem,” “seek,” “outlook,” and similar expressions that predict or indicate future events or trends, or that are not statements of historical matters. Forward-looking statements are predictions, projections, and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. These statements are based on various assumptions, whether or not identified in this press release. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as and must not be relied on by an investor as a guarantee, an assurance, a prediction, or a definitive statement of fact or probability. Actual events and circumstances are very difficult or impossible to predict and will differ from the assumptions. Many actual events and circumstances are beyond the control of
Readers are cautioned not to put undue reliance on forward-looking statements;
|
||||||||
CONDENSED CONSOLIDATED BALANCE SHEETS |
||||||||
(In thousands, except share and per share data) |
||||||||
|
|
|
|
|
||||
ASSETS |
|
(Unaudited) |
|
|
||||
CURRENT ASSETS: |
|
|
|
|
||||
Cash and cash equivalents |
$ |
52,468 |
|
$ |
15,275 |
|
||
Marketable securities |
|
129,910 |
|
|
— |
|
||
Accounts receivable, net |
|
147 |
|
|
156 |
|
||
Inventories, net |
|
4,852 |
|
|
2,655 |
|
||
Prepaid and other current assets |
|
6,701 |
|
|
1,396 |
|
||
Total current assets |
|
194,078 |
|
|
19,482 |
|
||
Property and equipment, net |
|
4,835 |
|
|
4,865 |
|
||
Restricted cash |
|
2,150 |
|
|
1,222 |
|
||
Other noncurrent assets |
|
169 |
|
|
316 |
|
||
Total assets |
$ |
201,232 |
|
$ |
25,885 |
|
||
|
|
|
|
|
||||
LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT) |
|
|
|
|
||||
CURRENT LIABILITIES: |
|
|
|
|
||||
Accounts payable |
|
4,039 |
|
|
1,807 |
|
||
Accrued expenses and other current liabilities |
|
4,077 |
|
|
3,356 |
|
||
Deferred revenue (including |
|
245 |
|
|
660 |
|
||
Convertible notes |
|
— |
|
|
29,079 |
|
||
Borrowings, net of issuance costs, current portion |
|
— |
|
|
2,693 |
|
||
Total current liabilities |
|
8,361 |
|
|
37,595 |
|
||
Deferred rent, noncurrent |
|
3,185 |
|
|
3,631 |
|
||
Private Placement Warrant liability |
|
156 |
|
|
— |
|
||
Borrowings, net of issuance costs, noncurrent |
|
— |
|
|
2,884 |
|
||
Total liabilities |
$ |
11,702 |
|
$ |
44,110 |
|
||
COMMITMENTS AND CONTINGENCIES |
|
|
|
|
||||
STOCKHOLDERS’ EQUITY (DEFICIT): |
|
|
|
|
||||
Preferred stock—$0.0001 par value per share: 1,000,000 shares authorized; no shares issued and outstanding |
|
— |
|
|
— |
|
||
Common stock—$0.0001 par value per share: 300,000,000 shares authorized; 154,565,671 and 101,286,645 shares issued and outstanding at |
|
15 |
|
|
10 |
|
||
Additional paid-in capital |
|
316,318 |
|
|
68,549 |
|
||
Accumulated other comprehensive loss |
|
(42 |
) |
|
— |
|
||
Accumulated deficit |
|
(126,761 |
) |
|
(86,784 |
) |
||
|
|
|
|
|
||||
Total stockholders’ equity (deficit) |
|
189,530 |
|
|
(18,225 |
) |
||
Total liabilities and stockholders’ equity (deficit) |
$ |
201,232 |
|
$ |
25,885 |
|
||
|
||||||||||||||||
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS |
||||||||||||||||
(In thousands, except share and per share data) |
||||||||||||||||
(Unaudited) |
||||||||||||||||
|
|
Three months ended
|
|
|
Nine months ended
|
|||||||||||
|
|
2021 |
|
|
2020 |
|
|
2021 |
|
|
2020 |
|||||
REVENUE: |
|
|
|
|
|
|
|
|
||||||||
Prototype sales (including |
$ |
127 |
|
$ |
87 |
|
$ |
588 |
|
$ |
150 |
|
||||
Development contracts (including |
|
— |
|
|
1,050 |
|
|
615 |
|
|
1,150 |
|
||||
|
|
|
|
|
|
|
|
|
||||||||
Total revenues |
|
127 |
|
|
1,137 |
|
|
1,203 |
|
|
1,300 |
|
||||
Cost of revenue |
|
466 |
|
|
317 |
|
|
1,537 |
|
|
464 |
|
||||
|
|
|
|
|
|
|
|
|
||||||||
Gross (loss) profit |
|
(339 |
) |
|
820 |
|
|
(334 |
) |
|
836 |
|
||||
|
|
|
|
|
|
|
|
|
||||||||
OPERATING EXPENSES: |
|
|
|
|
|
|
|
|
||||||||
Research and development (1) |
|
7,468 |
|
|
3,247 |
|
|
19,030 |
|
|
11,207 |
|
||||
Sales and marketing (1) |
|
2,991 |
|
|
672 |
|
|
6,489 |
|
|
2,610 |
|
||||
General and administrative (1) |
|
6,086 |
|
|
1,650 |
|
|
13,846 |
|
|
4,862 |
|
||||
|
|
|
|
|
|
|
|
|
||||||||
Total operating expenses |
|
16,545 |
|
|
5,569 |
|
|
39,365 |
|
|
18,679 |
|
||||
|
|
|
|
|
|
|
|
|
||||||||
LOSS FROM OPERATIONS |
|
(16,884 |
) |
|
(4,749 |
) |
|
(39,699 |
) |
|
(17,843 |
) |
||||
|
|
|
|
|
|
|
|
|
||||||||
OTHER INCOME (EXPENSE): |
|
|
|
|
|
|
|
|
||||||||
Change in fair value of embedded derivative liability and warrant liability |
|
341 |
|
|
1,366 |
|
|
222 |
|
|
1,284 |
|
||||
Gain on PPP loan forgiveness |
|
— |
|
|
— |
|
|
2,297 |
|
|
— |
|
||||
Interest income and other |
|
69 |
|
|
6 |
|
|
74 |
|
|
19 |
|
||||
Interest expense and other |
|
(919 |
) |
|
(401 |
) |
|
(2,871 |
) |
|
(955 |
) |
||||
|
|
|
|
|
|
|
|
|
||||||||
Total other income (expense), net |
|
(509 |
) |
|
971 |
|
|
(278 |
) |
|
348 |
|
||||
Provision for income tax expense |
|
— |
|
|
— |
|
|
— |
|
|
— |
|
||||
|
|
|
|
|
|
|
|
|
||||||||
Net loss |
$ |
(17,393 |
) |
$ |
(3,778 |
) |
$ |
(39,977 |
) |
$ |
(17,495 |
) |
||||
Net unrealized loss on available-for-sale securities |
|
(42 |
) |
|
— |
|
|
(42 |
) |
|
— |
|
||||
Comprehensive loss |
$ |
(17,435 |
) |
$ |
(3,778 |
) |
$ |
(40,019 |
) |
$ |
(17,495 |
) |
||||
PER SHARE DATA |
|
|
|
|
|
|
|
|
||||||||
Net loss per common share (basic and diluted) |
$ |
(0.15 |
) |
$ |
(0.04 |
) |
$ |
(0.39 |
) |
$ |
(0.17 |
) |
||||
Weighted average common shares outstanding (basic and diluted) |
|
114,891,595 |
|
|
103,155,756 |
|
|
102,953,263 |
|
|
103,054,374 |
|
(1) Includes stock-based compensation as follows (in thousands): |
||||||||||||||||
|
|
Three months ended
|
|
Nine months ended
|
||||||||||||
|
|
2021 |
|
2020 |
|
2021 |
|
2020 |
||||||||
Research and development expense |
$ |
665 |
$ |
93 |
$ |
2,062 |
$ |
341 |
||||||||
Sales and marketing |
|
398 |
|
35 |
|
1,171 |
|
116 |
||||||||
General and administrative |
|
1,229 |
|
144 |
|
3,289 |
|
358 |
||||||||
Total stock-based compensation |
$ |
2,292 |
$ |
272 |
$ |
6,522 |
$ |
815 |
|
||||||||
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS |
||||||||
(In thousands, except share and per share data) |
||||||||
(Unaudited) |
||||||||
|
|
Nine months ended |
||||||
|
|
2021 |
|
2020 |
||||
|
|
|
|
|
||||
CASH FLOWS FROM OPERATING ACTIVITIES: |
|
|
|
|
||||
Net loss |
$ |
(39,977 |
) |
$ |
(17,495 |
) |
||
Adjustments to reconcile net loss to net cash used in operating activities: |
|
|
|
|
||||
Depreciation and amortization |
|
769 |
|
|
679 |
|
||
Change in fair value of embedded derivative liability and warrant liability |
|
(222 |
) |
|
(1,284 |
) |
||
Noncash gain on PPP loan forgiveness |
|
(2,297 |
) |
|
— |
|
||
Stock-based compensation |
|
6,522 |
|
|
815 |
|
||
Amortization of issuance costs |
|
725 |
|
|
45 |
|
||
Amortization of debt discount |
|
752 |
|
|
509 |
|
||
Amortization of premiums on marketable securities |
|
47 |
|
|
— |
|
||
Other |
|
286 |
|
|
116 |
|
||
Changes in operating assets and liabilities: |
|
|
|
|
||||
Accounts receivable, net |
|
9 |
|
|
(91 |
) |
||
Inventories, net |
|
(2,197 |
) |
|
(414 |
) |
||
Prepaid and other current assets |
|
(5,305 |
) |
|
3,832 |
|
||
Other noncurrent assets |
|
(142 |
) |
|
108 |
|
||
Accounts payable |
|
840 |
|
|
(230 |
) |
||
Accrued expenses and other current liabilities |
|
1,417 |
|
|
44 |
|
||
Deferred rent |
|
(400 |
) |
|
(391 |
) |
||
Deferred revenue |
|
(415 |
) |
|
(201 |
) |
||
Net cash used in operating activities |
$ |
(39,588 |
) |
$ |
(13,958 |
) |
||
CASH FLOWS FROM INVESTING ACTIVITIES: |
|
|
|
|
||||
Purchase of property and equipment |
|
(713 |
) |
|
(4,017 |
) |
||
Purchase of available-for-sale securities |
|
(129,999 |
) |
|
— |
|
||
Net cash used in investing activities |
$ |
(130,712 |
) |
$ |
(4,017 |
) |
||
CASH FLOWS FROM FINANCING ACTIVITIES: |
|
|
|
|
||||
Proceeds from the exercise of stock options |
$ |
100 |
|
$ |
128 |
|
||
Proceeds from business combination and PIPE financing |
|
256,811 |
|
|
— |
|
||
Transaction costs related to business combination and PIPE financing |
|
(47,775 |
) |
|
— |
|
||
Proceeds from the issuance of convertible notes |
|
8,045 |
|
|
12,596 |
|
||
Proceeds from bank loans |
|
10,000 |
|
|
2,270 |
|
||
Principal payments on bank loans |
|
(13,333 |
) |
|
(444 |
) |
||
Payments of deferred financing costs |
|
(3,210 |
) |
|
— |
|
||
Payments of debt issuance costs |
|
(717 |
) |
|
(122 |
) |
||
Repurchase of stock options |
|
(1,500 |
) |
|
— |
|
||
Net cash provided by financing activities |
$ |
208,421 |
|
$ |
14,428 |
|
||
NET INCREASE (DECREASE) IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH |
|
38,121 |
|
|
(3,547 |
) |
||
CASH, CASH EQUIVALENTS AND RESTRICTED CASH—Beginning of period |
|
16,497 |
|
|
8,205 |
|
||
CASH, CASH EQUIVALENTS AND RESTRICTED CASH—Ending |
$ |
54,618 |
|
$ |
4,658 |
|
||
|
||||||||||||||||
RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES |
||||||||||||||||
ADJUSTED EBITDA |
||||||||||||||||
(In thousands, except share and per share data) |
||||||||||||||||
(Unaudited) |
||||||||||||||||
|
|
Three months ended
|
|
|
Nine months ended
|
|||||||||||
|
|
2021 |
|
|
2020 |
|
|
2021 |
|
|
2020 |
|||||
GAAP net loss |
$ |
(17,393 |
) |
$ |
(3,778 |
) |
$ |
(39,977 |
) |
$ |
(17,495 |
) |
||||
Non-GAAP adjustments: |
|
|
|
|
|
|
|
|
||||||||
Stock-based compensation |
|
2,292 |
|
|
272 |
|
|
6,522 |
|
|
815 |
|
||||
Expenses related to registration statement on Form S-1 on behalf of selling stockholders |
|
1,773 |
|
|
— |
|
|
2,198 |
|
|
— |
|
||||
Change in fair value of embedded derivative and warrant liabilities |
|
(341 |
) |
|
(1,366 |
) |
|
(222 |
) |
|
(1,284 |
) |
||||
Gain on PPP loan forgiveness |
|
— |
|
|
— |
|
|
(2,297 |
) |
|
— |
|
||||
Non-GAAP net loss |
$ |
(13,669 |
) |
$ |
(4,872 |
) |
$ |
(33,776 |
) |
$ |
(17,964 |
) |
||||
Depreciation and amortization expense |
|
271 |
|
|
259 |
|
|
769 |
|
|
679 |
|
||||
Interest income and other |
|
(69 |
) |
|
(6 |
) |
|
(74 |
) |
|
(19 |
) |
||||
Interest expense and other |
|
919 |
|
|
401 |
|
|
2,871 |
|
|
955 |
|
||||
Adjusted EBITDA |
|
(12,548 |
) |
|
(4,218 |
) |
|
(30,210 |
) |
|
(16,349 |
) |
||||
|
||||||||||||||||
RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES |
||||||||||||||||
EARNINGS LOSS PER SHARE |
||||||||||||||||
(In thousands, except share and per share data) |
||||||||||||||||
(Unaudited) |
||||||||||||||||
|
|
Three months ended
|
|
|
Nine months ended
|
|||||||||||
|
|
2021 |
|
|
2020 |
|
|
2021 |
|
|
2020 |
|||||
GAAP net loss |
$ |
(17,393 |
) |
$ |
(3,778 |
) |
$ |
(39,977 |
) |
$ |
(17,495 |
) |
||||
Non-GAAP net loss |
$ |
(13,669 |
) |
$ |
(4,872 |
) |
$ |
(33,776 |
) |
$ |
(17,964 |
) |
||||
GAAP net loss per share attributable to common stockholders:: |
|
|
|
|
|
|
|
|
||||||||
Basic and diluted |
$ |
(0.15 |
) |
$ |
(0.04 |
) |
$ |
(0.39 |
) |
$ |
(0.17 |
) |
||||
Non-GAAP net loss per share attributable to common stockholders: |
|
|
|
|
|
|
|
|
||||||||
Basic and diluted |
$ |
(0.12 |
) |
$ |
(0.05 |
) |
$ |
(0.33 |
) |
$ |
(0.17 |
) |
||||
Shares used in computing GAAP net loss per share attributable to common stockholders: |
|
|
|
|
|
|
|
|
||||||||
Basic and diluted |
|
114,891,595 |
|
|
103,155,756 |
|
|
102,953,263 |
|
|
103,054,374 |
|
||||
Shares used in computing Non-GAAP net loss per share attributable to common stockholders: |
|
|
|
|
|
|
|
|
||||||||
Basic and diluted |
|
114,891,595 |
|
|
103,155,756 |
|
|
102,953,263 |
|
|
103,054,374 |
|
||||
View source version on businesswire.com: https://www.businesswire.com/news/home/20211111005690/en/
Media Contact:
jennifer@aeye.ai
925-400-4366
Investors:
AEye@finprofiles.com
310-622-8230
AEye@finprofiles.com
310-622-8489
Source: